Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A look at 3 forms of fatty liver disease: Non-Alcoholic Fatty Liver, Non-Alcoholic Fatty Liver Disease, and Non-Alcoholic Steatohepatitis
Using a two-part testing plan could help identify those with advanced liver fibrosis among people with type 2 diabetes.
Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.
People with advanced liver cirrhosis are at greater risk for severe COVID-19 illness and death.
Researchers reported significant changes in liver, cardiovascular and diabetes markers.
Liver complications, heart disease and non-liver cancers also account for most deaths among people with hepatitis B or C.
Researchers recommend screening for fatty liver disease within this population.
Research proved that those with liver disease may reduce fibrosis by drinking 1 to 3 cups of this dark brew each day.
As with HIV-negative individuals, non-alcoholic fatty liver disease is tied to diabetes and irregular blood lipids in those with HIV.
A distinct set of microbes sets apart people with advanced fibrosis from those with minimal fibrosis.
NAFLD is the leading indicator of mortality among Medicare beneficiaries with hepatocellular carcinoma.
A fifth of the worldwide population with fatty liver disease consists of lean people.
The profile of chronic liver disease has changed due to obesity trends and advances in the treatment of hepatitis C.
Exercising for a longer period of time was especially linked to a reduced risk of death from cardiovascular conditions.
The injectable hormone helps reduce inflammation and fibrosis associated with NAFLD in this population.
Studies of PPAR agonists have yielded mixed results for people with fatty liver disease.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.